Crispr Therapeutics (NASDAQ:CRSP) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday, January 3rd, ValuEngine reports.

A number of other analysts have also recently weighed in on the company. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Canaccord Genuity raised their price target on Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a research note on Wednesday, November 20th. BidaskClub cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 1st. Goldman Sachs Group raised their price target on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Finally, Roth Capital raised their price target on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $71.38.

Shares of NASDAQ CRSP traded down $2.00 during mid-day trading on Friday, hitting $59.90. The company had a trading volume of 1,290,717 shares, compared to its average volume of 954,273. The company has a market capitalization of $3.31 billion, a PE ratio of -17.41 and a beta of 3.20. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. Crispr Therapeutics has a 1-year low of $29.34 and a 1-year high of $74.00. The business’s 50-day simple moving average is $65.94 and its 200 day simple moving average is $51.65.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. On average, analysts expect that Crispr Therapeutics will post 0.65 EPS for the current year.

In related news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $412,500. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,118 shares of company stock worth $3,620,760. Corporate insiders own 21.40% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nikko Asset Management Americas Inc. boosted its holdings in Crispr Therapeutics by 48.4% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after purchasing an additional 906,006 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after acquiring an additional 121,176 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of Crispr Therapeutics during the 3rd quarter valued at approximately $21,167,000. Morgan Stanley lifted its position in shares of Crispr Therapeutics by 6.1% during the 2nd quarter. Morgan Stanley now owns 284,984 shares of the company’s stock valued at $13,423,000 after acquiring an additional 16,361 shares during the period. Finally, Royal Bank of Canada lifted its position in shares of Crispr Therapeutics by 75.1% during the 2nd quarter. Royal Bank of Canada now owns 120,425 shares of the company’s stock valued at $5,672,000 after acquiring an additional 51,665 shares during the period. 49.82% of the stock is currently owned by institutional investors.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: Dividend Achievers

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link